From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

被引：34

作者：

Leong, Darryl P. ^{[1
,2
]}

McMurray, John J., V ^{[3
]}

Joseph, Philip G. ^{[1
,2
]}

Yusuf, Salim ^{[1
,2
]}

机构：

[1] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 74卷 / 05期

关键词：

ACE-I; ARB; ARNI; coronary disease; heart failure; CONVERTING-ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; RENIN-ANGIOTENSIN SYSTEM; ACUTE MYOCARDIAL-INFARCTION; 2013 ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; EJECTION FRACTION; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIAL; HIGH-RISK;

D O I：

10.1016/j.jacc.2019.04.068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies. (C) 2019 by the American College of Cardiology Foundation.

引用

页码：683 / 698

页数：16

共 73 条

[1] Anglotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function - A systematic review and meta-analysis of randomized controlled trials [J].

Al-Mallah, MH ;

Tleyjeh, IM ;

Abdel-Latif, AA ;

Weaver, WD .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) :1576-1583

[2] Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern? [J].

Bakris, GL ;

Weir, MR .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :685-693

[3]

BALL SG, 1993, LANCET, V342, P821

[4] Angiotensin-converting Enzyme Inhibitor-induced Angioedema [J].

Bezalel, Shira ;

Mahlab-Guri, Keren ;

Asher, Ilan ;

Werner, Ben ;

Sthoeger, Zev Moshe .

AMERICAN JOURNAL OF MEDICINE, 2015, 128 (02) :120-125

[5] THE EFFECT OF A NATRIURETIC ATRIAL EXTRACT ON RENAL HEMODYNAMICS AND URINARY-EXCRETION IN ANESTHETIZED RATS [J].

BORENSTEIN, HB ;

CUPPLES, WA ;

SONNENBERG, H ;

VERESS, AT .

JOURNAL OF PHYSIOLOGY-LONDON, 1983, 334 (JAN) :133-140

[6]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

[7] The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure [J].

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) :1029-1041

[8] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[9]

Caldeira D, 2012, AM J CARDIOVASC DRUG, V12, P263, DOI 10.2165/11599990-000000000-00000

[10] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].

Cohn, JN ;

Tognoni, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675

← 1 2 3 4 5 6 7 8 →